Evidence map›Paper›PMID 41028263›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2026

Implementing Photodynamic Therapy to Activate the IFN-1 Pathway in Melanoma Cells: A Protocol for Inducing Immunogenic Cell Death and Enhancing Dendritic Cell Maturation.

Fátima María Mentucci, Agustina Ercole, Natalia Belén Rumie Vittar, María Julia Lamberti

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Fátima María MentucciINBIAS-UNRC-CONICET, Río Cuarto, Córdoba, Argentina.
Agustina ErcoleDepartamento de Biología Molecular, Facultad de Ciencias Exactas, Físico-Químicas y Naturales, Universidad Nacional de Río Cuarto, Río Cuarto, Córdoba, Argentina.
Natalia Belén Rumie VittarINBIAS-UNRC-CONICET, Río Cuarto, Córdoba, Argentina.
María Julia LambertiINBIAS-UNRC-CONICET, Río Cuarto, Córdoba, Argentina. mlamberti@exa.unrc.edu.ar.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This chapter outlines a detailed protocol for employing photodynamic therapy (PDT) to induce immunogenic cell death (ICD) in melanoma cells, specifically targeting the type-I-interferons (IFN-1) signaling pathway. Recent studies have highlighted the role of IFN-1 in the immune response against cancer, acting as novel damage-associated molecular patterns (DAMPs) that bridge innate and adaptive immunity. Our approach utilizes methyl-aminolevulinate (Me-ALA) to induce the production of endogenous photosensitizer protoporphyrin IX (PpIX), which preferentially accumulates in the endoplasmic reticulum (ER). Activation of PpIX through visible light irradiation triggers oxidative stress-induced apoptotic cell death. This chapter provides a step-by-step guide to replicate these conditions, which have been shown to significantly upregulate IFN-α/β transcripts in B16-OVA melanoma cells, leading to enhanced expression of GMP-AMP synthase (cGAS) and interferon-stimulated genes (ISGs) like CXCL10, MX1, and ISG15. We further discuss the consequential IFN-1-dependent-phenotypic maturation of monocyte-derived dendritic cells (DCs), evidenced by increased expression of co-stimulatory molecules such as CD80 and MHC-II and enhanced tumor-directed chemotaxis. By detailing the protocol for this novel application of PDT, this chapter aims to facilitate its integration into immunotherapy regimens, providing a comprehensive toolkit for researchers and clinicians aiming to harness the antitumor potential of the IFN-1 pathway.

Indexed as

Dendritic CellsImmunogenic Cell DeathInterferon Type IMelanomaPhotochemotherapyAminolevulinic AcidAnimalsApoptosisCell Line, TumorHumansMicePhotosensitizing AgentsProtoporphyrinsSignal TransductionAminolevulinic AcidInterferon Type IPhotosensitizing Agentsprotoporphyrin IXProtoporphyrinsCancerIFNARImmunotherapyMe-ALATumor immunology

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.